GlassScriptPhysician profile
Annette M Moore
NPI 1609818467
$2,626.01
in general payments reported to CMS, 2019-2025
40 companies · $93.93 in 2025
The $93.93 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,703 · 2020: $388 · 2021: $31.27 · 2022: $117 · 2023: $68.28 · 2024: $225 · 2025: $93.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $231.51 | 2019-2024 | Keytruda |
| Genentech USA, INC. | $213.53 | 2019-2020 | |
| Pfizer INC. | $201.72 | 2019-2022 | |
| Tempus Ai, INC | $145.52 | 2024 | |
| Hologic Sales and Service, LLC | $144.89 | 2022-2024 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Eisai INC. | $126.82 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $122.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $114.96 | 2019-2020 | |
| Celgene Corporation | $97.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $85.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $76.07 | 2019-2020 | |
| Genzyme Corporation | $75.91 | 2019-2020 | |
| Janssen Biotech, INC. | $68.94 | 2019-2020 | |
| Incyte Corporation | $64.26 | 2019 | |
| Lilly USA, LLC | $61.70 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $59.72 | 2023-2025 | Slynd |
| Clovis Oncology, INC. | $58.25 | 2019-2020 | |
| Millicent US INC | $56.40 | 2025 | Femlyv, Intrarosa |
| Amgen INC. | $53.97 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.00 | 2019 | |
| Daiichi Sankyo INC. | $47.56 | 2019-2020 | |
| Exelixis INC. | $46.72 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $43.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.04 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.78 | 2019 | |
| Gilead Sciences, INC. | $35.42 | 2021-2025 | |
| Tersera Therapeutics LLC | $33.10 | 2019 | |
| Abbvie INC. | $31.59 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $25.09 | 2019 | |
| Seagen INC. | $24.25 | 2019-2020 | |
| Kite Pharma, INC. | $18.56 | 2020 | |
| Puma Biotechnology, INC. | $17.12 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.98 | 2019 | |
| Aurobindo Pharma USA, INC. | $15.39 | 2019 | |
| Verastem, INC. | $14.91 | 2019 | |
| Dova Pharmaceuticals | $13.73 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.70 | 2019 | |
| Glaxosmithkline, LLC. | $13.40 | 2019 | |
| Tesaro, INC. | $13.29 | 2019 | |
| Rigel Pharmaceuticals, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.